JuSpace: A tool for spatial correlation analyses of magnetic resonance imaging data with nuclear imaging derived neurotransmitter maps

Recent studies have shown that drug-induced spatial alteration patterns in resting state functional activity as measured using magnetic resonance imaging (rsfMRI) are associated with the distribution of specific receptor systems targeted by respective compounds. Based on this approach, we introduce a toolbox (JuSpace) allowing for cross-modal correlation of MRI- based measures with nuclear imaging derived estimates covering various neurotransmitter systems including dopaminergic, serotonergic, noradrenergic, and GABAergic (gamma- aminobutric acid) neurotransmission. We apply JuSpace to two datasets covering Parkinson’s disease patients (PD) and risperidone-induced changes in rsfMRI and cerebral blood flow (CBF). Consistently with the predominant neurodegeneration of dopaminergic and serotonergic system in PD, we find significant spatial associations between rsfMRI activity alterations in PD and dopaminergic (D2) and serotonergic systems (5-HT1b). Risperidone induced CBF alterations were correlated with its main targets in serotonergic and dopaminergic systems. JuSpace provides a biologically meaningful framework for linking neuroimaging to underlying neurotransmitter information.

[1]  N. Tzourio-Mazoyer,et al.  Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain , 2002, NeuroImage.

[2]  P. F. M. Janssen,et al.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding , 1996, Psychopharmacology.

[3]  M. Fasshauer,et al.  Central noradrenaline transporter availability in highly obese, non-depressed individuals , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  Rebecca C. Knickmeyer,et al.  ENIGMA and global neuroscience: A decade of large-scale studies of the brain in health and disease across more than 40 countries , 2019, Biological Psychiatry.

[5]  Zsolt Szabo,et al.  Quantitative PET Studies of the Serotonin Transporter in MDMA Users and Controls Using [11C]McN5652 and [11C]DASB , 2005, Neuropsychopharmacology.

[6]  Andrew T. Drysdale,et al.  Resting-state connectivity biomarkers define neurophysiological subtypes of depression , 2016, Nature Medicine.

[7]  Tobias C. Wood,et al.  An investigation of regional cerebral blood flow and tissue structure changes after acute administration of antipsychotics in healthy male volunteers , 2018, Human brain mapping.

[8]  M. Scheinin,et al.  Sensitivity of [11C]ORM-13070 to increased extracellular noradrenaline in the CNS – a PET study in human subjects , 2015, Psychopharmacology.

[9]  Federico E. Turkheimer,et al.  Increased cerebral blood flow after single dose of antipsychotics in healthy volunteers depends on dopamine D2 receptor density profiles , 2018, NeuroImage.

[10]  Thomas E. Nichols,et al.  The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data , 2014, Brain Imaging and Behavior.

[11]  Karl J. Friston,et al.  Movement‐Related effects in fMRI time‐series , 1996, Magnetic resonance in medicine.

[12]  Garry D. Honey,et al.  Patients with autism spectrum disorders display reproducible functional connectivity alterations , 2019, Science Translational Medicine.

[13]  A. Meyer-Lindenberg,et al.  Intermediate phenotypes and genetic mechanisms of psychiatric disorders , 2006, Nature Reviews Neuroscience.

[14]  J. Hogg.  Magnetic resonance imaging. , 1994, Journal of the Royal Naval Medical Service.

[15]  P. Expert,et al.  MENGA: A New Comprehensive Tool for the Integration of Neuroimaging Data and the Allen Human Brain Transcriptome Atlas , 2016, PloS one.

[16]  Neda Bernasconi,et al.  Cortical thickness analysis in temporal lobe epilepsy , 2010, Neurology.

[17]  Mikel Aickin.  Invalid Permutation Tests , 2010, Int. J. Math. Math. Sci..

[18]  P. Hluštík,et al.  Effects of spatial smoothing on fMRI group inferences. , 2008, Magnetic resonance imaging.

[19]  Siegfried Kasper,et al.  Normative database of the serotonergic system in healthy subjects using multi-tracer PET , 2012, NeuroImage.

[20]  F. Niccolini,et al.  Serotonin transporter in Parkinson's disease: A meta‐analysis of positron emission tomography studies , 2016, Annals of neurology.

[21]  Thomas Fritz,et al.  Test–retest measurements of dopamine D1-type receptors using simultaneous PET/MRI imaging , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  J D Speelman,et al.  [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[23]  Donald Sashin,et al.  Test–retest variability of serotonin 5‐HT2A receptor binding measured with positron emission tomography and [18F]altanserin in the human brain , 1998, Synapse.

[24]  Matti Laine,et al.  Long-Term Test–Retest Reliability of Striatal and Extrastriatal Dopamine D2/3 Receptor Binding: Study with [11C]Raclopride and High-Resolution PET , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[25]  Karl J. Friston,et al.  A Voxel-Based Morphometric Study of Ageing in 465 Normal Adult Human Brains , 2001, NeuroImage.

[26]  D. Greve,et al.  A high-resolution in vivo atlas of the human brain's serotonin system. , 2016, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[27]  Ming Yang,et al.  Brain annotation toolbox: exploring the functional and genetic associations of neuroimaging results , 2019, Bioinform..

[28]  Rupert Lanzenberger,et al.  Topologically Guided Prioritization of Candidate Gene Transcripts Coexpressed with the 5-HT1A Receptor by Combining In Vivo PET and Allen Human Brain Atlas Data , 2020, Cerebral cortex.

[29]  Osama Mawlawi,et al.  Imaging Human Mesolimbic Dopamine Transmission with Positron Emission Tomography: I. Accuracy and Precision of D2 Receptor Parameter Measurements in Ventral Striatum , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[30]  Eric C Leuthardt,et al.  Integration of resting state functional MRI into clinical practice - A large single institution experience , 2018, PloS one.

[31]  J. Shimony,et al.  Resting-State fMRI: A Review of Methods and Clinical Applications , 2013, American Journal of Neuroradiology.

[32]  Karl J. Friston,et al.  Statistical parametric maps in functional imaging: A general linear approach , 1994 .

[33]  I. Melle,et al.  Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium , 2016, Molecular Psychiatry.

[34]  Mario Quarantelli,et al.  Relationship between simultaneously acquired resting-state regional cerebral glucose metabolism and functional MRI: A PET/MR hybrid scanner study , 2015, NeuroImage.

[35]  F. Gómez,et al.  Elaboración de una plantilla de SPM para la normalización de imágenes de PET con 18F-DOPA , 2018 .

[36]  Zhen Yan,et al.  Serotonin Receptors Modulate GABAA Receptor Channels through Activation of Anchored Protein Kinase C in Prefrontal Cortical Neurons , 2001, The Journal of Neuroscience.

[37]  Sean D Sullivan,et al.  Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[38]  Christopher H. Chatham,et al.  Cerebral blood flow predicts differential neurotransmitter activity , 2017, bioRxiv.

[39]  Paul J. Laurienti,et al.  Neuroinformatics Original Research Article Materials and Methods Study Participants , 2022 .

[40]  J. Dukart,et al.  Test-retest reliability of task-based and resting-state blood oxygen level dependence and cerebral blood flow measures , 2018, bioRxiv.

[41]  G. Egan,et al.  Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington's disease , 2008, Brain Research Reviews.